Status:
SUSPENDED
Immunomodulatory Effect of Macrolides in Naturally Occurring Influenza Virus Infections in the Community
Lead Sponsor:
The University of Hong Kong
Conditions:
Influenza, Human
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
The investigators propose a double-blind randomised placebo-controlled study in naturally occurring influenza virus infections in the community setting to compare the impact of a short course of clari...
Detailed Description
Background: Influenza continues to pose an imminent threat to public health through seasonal epidemics and occasion pandemics with significant impact on morbidity and mortality. Increasing attention h...
Eligibility Criteria
Inclusion
- Adults aged between 18-60
- Presenting with symptoms of acute URTI (at least two among the following symptoms: body temperature ≥37.8°C, cough, rhinorrhea, sore throat, headache, myalgia/arthralgia) to university health clinics within 48 hours of illness onset.
Exclusion
- Allergy to clarithromycin or any other macrolides or the ingredients in the tablets, which include microcrystalline cellulose, croscarmelose sodium, magnesium stearate and povidon will be excluded.
- Patients with a history of chronic liver disease, or any active lung, heart or renal diseases requiring regular medication, or any underlying immunocompromised condition or receiving immunosuppressive agents will also be excluded.
Key Trial Info
Start Date :
June 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03824847
Start Date
June 1 2023
End Date
September 1 2024
Last Update
November 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
School of Public Health, The University of Hong Kong
Hong Kong, Hong Kong